SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Hyperliquid is a layer one (L1) blockchain best known for perpetual futures and spot trading. Beyond its flagship DEX trading platform, the ecosystem supports borrowing, lending, real world assets (RWAs), and a full-fledged Ethereum Virtual Machine (EVM), making it a leading force in decentralized finance (defi).   Just as electronic trading dramatically improved markets in the 2000s, Hyperliquid offers an opportunity for a massive technical upgrade of the existing financial system through a transparent, efficient, and resilient blockchain. HYPE is the native token of the Hyperliquid blockchain, with a maximum supply of 1 billion.

Hype

HYPE is trending due to its dominance in the high-volume perpetual futures market and strong institutional interest, with the community closely tracking its record-breaking token burn and fee generation. Investors are actively discussing the potential for a massive breakout as the project attracts increased buying pressure and positions itself as a critical layer-1 infrastructure play.

Polkadot is a platform that allows diverse blockchains to transfer messages, including value, in a trust-free fashion; sharing their unique features while pooling their security. In brief, Polkadot is a scalable heterogeneous multi-chain technology.  Polkadot is heterogeneous because it is entirely flexible and makes no assumption about the nature or structure of the chains in the network. Even non-blockchain systems or data structures can become parachains if they fulfill a set of criteria.  Polkadot may be considered equivalent to a set of independent chains (e.g. a set containing Ethereum, Ethereum Classic, Namecoin and Bitcoin) except with important additions: pooled security and trust-free interchain transactability.  Many of the native parachains of Polkadot will be written using a Polkadot Runtime Environment SDK (e.g. Parity Technologies' Substrate).

Polkadot

Polkadot is trending as investors debate its long-term potential following a transition to a capped supply model, with community sentiment divided between those betting on a technical turnaround and critics who remain skeptical of its adoption metrics. Discussions are heavily focused on its future as an enterprise-grade network and the impact of upcoming upgrades on its ability to compete with other major blockchain ecosystems.

Taylor Morrison Home Corp. engages in the business of residential homebuilding and the development of lifestyle communities. It operates through the following segments: East, Central, West, and Financial Services. The East segment includes operations in Atlanta, Charlotte, Chicago, Orlando, Raleigh, Southwest Florida, and Tampa regions. The Central segment consists of Austin, Dallas, Denver, Houston, and Indianapolis. The West segment covers Bay Area, Las Vegas, Phoenix, Portland, Sacramento, Seattle, and Southern California. The Financial Services segment refers to Taylor Morrison Home Funding, Inspired Title Services, and Taylor Morrison Insurance Services. The company was founded in 1936 and is headquartered in Scottsdale, AZ.

Taylor Morrison Home Corp.

Taylor Morrison Home Corp. is in the spotlight following news of a proposed acquisition by Berkshire Hathaway, fueling significant community debate over the valuation and the broader implications for the homebuilding sector. Investors are closely monitoring the potential ripple effects of this deal on industry peers as sentiment shifts regarding housing affordability and market confidence.

Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.

Revolution Medicines Inc

Revolution Medicines is seeing intense market interest and positive sentiment driven by the presentation of pivotal Phase 3 clinical data for daraxonrasib, which significantly extended survival in patients with metastatic pancreatic cancer. The community is actively discussing the drug's potential as a new standard of care, the significance of the standing ovation the data received, and ongoing debates comparing the company's valuation and clinical profile to peers in the oncology space.

This has been pretty requested, so here's a short explainer of what $Staccana is:  @STACCoverflow has cooked up a Solana fork using some tech that was created, but never utilized since Solana cannot rollback or change inherent promises the chain makes. Here are the promises that Staccana chain makes:  a. Token transfers are encrypted by default b. Launches use frequent-batch auctions (MEV is not possible on this chain)  I've been coordinating with Stacc to help create a flywheel for this meme coin and the native ssSOL token. If you want early access to the chain, best rewards, and to become a part of this ecosystem you want to be invested in $Staccana.  Said flywheel is being cooked by Stacc as we speak, and the plan is to release Staccana main net on May 16th. I will be contributing the locked 4.6% supply to LPs for the flywheel.  Creator fees will be used to bootstrap the network, incentivize early users, and to add to the Stacanna treasury.  73edX6xoGY4v5y2hzuKdrUbJXLntqgmo74au1Ki1pump

Solana Fork Staccana

Staccana is gaining momentum as community members debate its potential, balancing excitement over a planned privacy-focused mainnet launch against skepticism regarding its origins as a meme-based asset. Traders are closely monitoring the project's low market cap, liquid staking narrative, and increasing transaction volume as indicators of potential early-stage growth.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

Summit Therapeutics is experiencing intense community focus and volatility ahead of the HARMONi-6 plenary session at ASCO, where investors are weighing potential paradigm-shifting survival data against concerns over regulatory hurdles for China-derived clinical results. While the community remains sharply divided between bulls betting on a disruptive oncology breakthrough and skeptics citing heavy short interest and regulatory risks, the upcoming data release is being widely treated as a pivotal binary catalyst for the stock.

Berkshire Hathaway, Inc. is a holding company, which engages in the provision of property and casualty insurance and reinsurance, utilities and energy, freight rail transportation, finance, manufacturing, and retailing services. It operates through the following segments: Insurance, Burlington Northern Santa Fe, LLC (BNSF), Berkshire Hathaway Energy (BHE), Pilot Travel Centers (PTC), Manufacturing, McLane, and Service and Retailing. The Insurance segment includes the underwriting of GEICO, Berkshire Hathaway Primary Group, and Berkshire Hathaway Reinsurance Group. The BNSF segment involves the operation of railroad systems. The BHE segment focuses on regulated electric and gas utility, power generation and distribution, and real estate brokerage activities. The PTC segment consists of managing travel centers and marketing of wholesale fuel. The Manufacturing segment refers to industrial, consumer and building products, home building, and related financial services. The McLane segment covers the wholesale distribution of groceries and non-food items. The Service and Retailing segment relates to the provision of shared aircraft ownership programs, aviation pilot training, electronic components distribution, retailing businesses, automobile dealerships and trailer, and furniture leasing services. The company was founded by Oliver Chace in 1839 and is headquartered in Omaha, NE.

Berkshire Hathaway Inc. - Ordinary Shares - Class A

Berkshire Hathaway is trending as shareholders analyze the company's record cash reserves of over $380 billion and strong earnings growth, even as uncertainty looms ahead of Warren Buffett's transition away from the CEO role. The community is actively debating the conglomerate's future strategy, its role as a defensive play in an AI-heavy market, and its potential to deploy capital as new leadership prepares to take the helm.

WorldFinancial

WorldFinancial (WLFI) is seeing intense debate as investors react to a governance proposal aimed at locking up a significant portion of the token supply and executing a massive token burn. Community sentiment is deeply divided, with some market participants viewing the move as a necessary supply shock that could trigger a recovery, while critics remain skeptical and continue to label the project a scam linked to the Trump family.

TRON is a decentralized blockchain-based operating system designed to accelerate the decentralization of the internet and its underlying infrastructure. It serves as a global settlement layer for stablecoins and everyday digital purchases, providing a high-throughput environment to support large-scale decentralized applications. The network is governed by a decentralized autonomous organization (DAO), which allows the community to manage the protocol without a central authority. Its primary value proposition includes a unique resource model that utilizes bandwidth and energy to allow for high transaction volumes without traditional fee spikes.  The platform functions as a smart contract platform that enables the creation of decentralized applications and is compatible with the Ethereum Virtual Machine, allowing developers to easily migrate applications. TRON operates using a Delegated Proof of Stake consensus mechanism where token holders vote for 27 Super Representatives to verify transactions and maintain the ledger. This structure is built for scalability and fast finality, aiming to handle more transactions per second than many established legacy blockchains. Users can interact with the ecosystem for various purposes, including decentralized finance (DeFi) through platforms like JustLend DAO and decentralized storage via the BitTorrent File System.  Value moves through the system via its native utility token, TRX, which facilitates transactions and grants users access to network resources. Holders can lock their TRX in a staking mechanism to gain TRON Power, which is used to vote on network rules and elect Super Representatives, earning rewards for securing the network. Established by the TRON Foundation and led by founder Justin Sun, the project has transitioned into a community-led DAO. The ecosystem is supported by strategic partnerships with major global entities, including Samsung, which integrated TRON into its blockchain keystore, as well as BitTorrent, Opera, and Swisscom Blockchain.

Tron

Tron is trending as investors monitor its resilience and high stablecoin transaction volume, alongside speculation regarding potential exchange listings and partnerships. The community remains focused on technical support levels and long-term accumulation strategies while debating the impact of ongoing network developments and broader market fluctuations.

PepsiCo, Inc. engages in the manufacture, marketing, distribution, and sale of beverages, food, and snacks. It operates through the following business segments: PepsiCo Foods North America (PFNA), PepsiCo Beverages North America (PBNA), International Beverages Franchise (IB Franchise), Europe, Middle East and Africa (EMEA), Latin America Foods (LatAm Foods), and Asia Pacific Foods. The PFNA segment refers to the food businesses in the United States and Canada. The PBNA segment includes beverage businesses in the United States and Canada. The IB Franchise segment involves the international franchise beverage businesses, as well as the SodaStream business. The EMEA segment pertains to food businesses and beverage businesses with company-owned bottlers in Europe, the Middle East, and Africa. The LatAm Foods segment consists of food businesses in Latin America. The Asia Pacific Foods segment is associated in food businesses in Asia Pacific, including China, Australia and New Zealand, as well as India. The company was founded by Donald M. Kendall, Sr. and Herman W. Lay in 1965 and is headquartered in Purchase, NY.

PepsiCo Inc

PepsiCo is trending following a double-beat earnings report that highlighted volume growth in its North American snack division after strategic price reductions. The community is actively discussing the company's dividend hike, the impact of its distribution deals on brands like Celsius, and broader debates over how the consumer staples sector is navigating current inflationary pressures and changing dietary trends.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

La Jolla Pharmaceutical Company is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics for chronic organ failure and cancer. GCS-100, the Company's lead product candidate, is a first-in-class inhibitor of galectin-3, a novel molecular target implicated in chronic organ failure and cancer. LJPC-501, the Company's second product candidate, is a natural peptide for the treatment of the hepatorenal syndrome.

LJPC
La Jolla Pharmaceutical Co.

Feed

News

Sentiment

Fundamentals

Info

Compact View

Latest LJPC News

LJPCLa Jolla Pharmaceutical Co.